The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
about
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospectsResidual macrovascular risk in 2013: what have we learned?Macrophage-independent regulation of reverse cholesterol transport by liver X receptors.Hyperlipidemia medication management in patients admitted for a myocardial infarction.Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: a reviewThe effects of treatment on lipoprotein subfractions evaluated by polyacrylamide gel electrophoresis in patients with autoimmune hypothyroidism and hyperthyroidismAdverse events following statin-fenofibrate therapy versus statin alone: a meta-analysis of randomized controlled trials.TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats.Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitusDyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatmentEfficacy of statin monotherapy or in combination with coenzyme a capsule in patients with metabolic syndrome and mixed dyslipidemia.The role of triglycerides in atherosclerosis.Lipid-related residual risk and renal function for occurrence and prognosis among patients with first-event acute coronary syndrome and normal LDL cholesterolBaseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies.On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: aComparisons of pharmacokinetics and NO-releasing of nitrofibriate and fenofibrate after oral administration in rats.The perception and knowledge of cardiovascular risk factors among medical students.Cardio-metabolic risk prediction should be superior to cardiovascular risk assessment in primary prevention of cardiovascular diseases.PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia.Dyslipidemia in the Arabian Gulf and its Impact on Cardiovascular Risk OutcomeReducing vascular events risk in patients with dyslipidaemia: an update for cliniciansPrevention of cardiovascular disease guided by total risk estimations--challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular PharmacoloPPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with HypertriglyceridemiaThe effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youthEffects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyThe Pleiotropic Effects of Atorvastatin on Stable Angina Patients: Evidence by Analysis of High-Density Lipoprotein Size and Subclasses, and Plasma mRNA.Compound K Attenuates the Development of Atherosclerosis in ApoE(-/-) Mice via LXRα ActivationApproach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetesTRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity.Overview of omega-3 Fatty Acid therapiesEfficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-blind, randomized, placebo-controlled study.Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.Effect of omega-3 fish oil on cardiovascular risk in diabetes.Management of dyslipidemia in the elderly population.Recent advances in the treatment of atherogenic dyslipidemia in type 2 diabetes mellitus.Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus.Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome?Icosapent ethyl for the treatment of hypertriglyceridemia.New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?
P2860
Q26829098-40C8E74E-3F71-4447-A489-79D92D70366EQ26996039-A98A2D90-3D02-4E5D-A51B-F6A8914A5BFBQ30371540-ACEB8DE2-F83B-4718-B95C-B7C9D0688F04Q34045514-AB096A1B-7E96-4943-A273-A9CDB1412C05Q34238630-2FADFE5A-A71D-4391-B892-4B09DBA05F55Q34410638-100423AB-217E-4732-8A50-DDA5CD49BCE6Q34549774-75E570C3-5632-47F0-8D90-D1BB92A6F93FQ34721238-C632D790-ED5C-4A07-8184-D478E823E310Q34757030-52D3F68E-F8FD-40F1-A02A-33B6E63DB677Q35029623-B88ECABA-1677-4470-8841-FB065DCDF487Q35387293-2682EDBA-8B1D-4A0A-9561-61979C18B4F8Q35602424-5EAC1D53-BF5A-4575-8D05-3B1395336C39Q35607759-CDC1898E-2B5F-4051-A9F6-46E07FD7D6DAQ35809770-FD8D6951-9401-4958-B499-292E9CAD1906Q35917224-2CB29457-D948-401C-A719-7D94E63FC3ABQ36043356-E4340F32-205D-4559-9407-975F2B3A1ED2Q36045185-9DE0AE3B-51ED-4DC5-9220-1675DE45B107Q36117824-98640B25-5B8F-4C50-812E-5D9EB81112D3Q36360452-646B9D9B-307F-4941-B365-81ECEB96AC15Q36373684-A09AA93A-4BC0-4A5E-98D2-3C86CDCC7F38Q36443768-8812CD38-B672-4AF9-8AA4-805B61E29C5CQ36613362-1EA97E81-028C-4E5E-9832-CCC71A9D3CD8Q36668641-5346F9AE-66D8-4392-B055-FE60E5B49769Q37031070-B4F53041-7368-473C-B9E7-6650BEA1B7A7Q37033651-27D5A97F-58A1-4318-A11F-5126C6690141Q37041300-8B22AC87-4C61-49A3-91AC-FF8B8AC078D2Q37134445-C6539C32-48C8-42B0-88BF-3A19F1A6BD39Q37308578-7FDE9A4F-5828-41E7-B9D0-F004A83F4510Q37414989-95AA447E-22A5-4F9D-A35B-A3F56C7EC99FQ37419411-0A9AA41E-7E8A-475A-AD1C-3B628B7462F8Q37436379-957FEF4D-CCFE-47C9-8148-2D7AADAC0C7DQ37472064-6EA4C66C-DBC1-4295-BB03-6FF558C7D8ECQ37763811-8134BF06-DD54-4C5E-93A5-A929C4A9205CQ37802082-5F1AD1AC-7C7F-45F9-BA43-A15C789A57DBQ37892300-AE552CD9-1267-4EB5-80C4-0D1EF2CAA043Q37973386-F492049F-690F-424A-A7EA-33718DE8E2BCQ37978926-14766AC0-6650-41F8-B32B-A419BF64B174Q38067362-AA6E4298-F6BA-437D-B70E-E1ECC1FF468BQ38108834-CC35243F-A65F-4E07-81EB-8C032717F4C4Q38126418-C592AAD9-FBEB-457A-8A49-71BAC2393809
P2860
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@en
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@nl
type
label
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@en
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@nl
prefLabel
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@en
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@nl
P2093
P2860
P50
P356
P1476
The Residual Risk Reduction In ...... risk in dyslipidaemic patient.
@en
P2093
Alberto Zambon
Christoph Wanner
Frank M Sacks
Gerd Assmann
Henry N Ginsberg
Jane K Stock
Jean-Marc Lablanche
Jorge Plutzky
M John Chapman
Michel P Hermans
P2860
P304
P356
10.3132/DVDR.2008.046
P407
P577
2008-11-01T00:00:00Z